Anti-wandering System for People With Intellectual Disability
Launched by THE UNIVERSITY OF HONG KONG · Mar 14, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new anti-wandering system designed to help keep individuals with intellectual disabilities safe in a day activity center and hostel. The main goals are to find out if this system can help care staff respond more quickly to alarms and reduce their workload when monitoring residents. The study will also explore how many alarms are triggered, how many of those alarms are false, and the overall benefits of this system compared to traditional methods of keeping residents safe.
To participate in the trial, residents of the study sites who are able to move around independently are eligible. Care staff who operate the system can also take part. If you or someone you know is interested, the trial is currently recruiting participants. Throughout the study, participants can expect to be monitored while using the anti-wandering system, and their experiences will help determine how effective this technology is in enhancing safety and support.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Inclusion criteria of residents:
- • • Residents of the study sites
- Inclusion criteria of care staff:
- • • Responsible for the operation of the anti-wandering system
- Exclusion Criteria:
- Exclusion criteria of residents:
- • • Not independently mobile (i.e. unable to walk around without care staff assistance)
- Exclusion criteria of care staff:
- • • Nil
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Yee Tak Cheung, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials